Ryan Kilgore

Ryan Kilgore

Auto-generated profile, based on publicly available information

Ryan Kilgore

Department of Chemical and Biomolecular Engineering, North Carolina State University, 911 Partners Way, Raleigh, NC 27695, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 September 2023 in Journal of Chromatography A
Verified
Journal Article
Closed access
RKRyan Kilgore
Ryan Kilgore
AMArianna Minzoni
Arianna Minzoni
Shriarjun ShastryShriarjun Shastry
Shriarjun Shastry
WSWill Smith
Will Smith
EBEduardo Barbieri
Eduardo Barbieri
SMStefano Menegatti
Stefano Menegatti

25 September 2024 in Journal of Chromatography A
Verified
Journal Article
Closed access
YWYuxuan Wu
Yuxuan Wu
EBEduardo Barbieri
Eduardo Barbieri
RKRyan E. Kilgore
Ryan E. Kilgore
BMBrandyn D. Moore
Brandyn D. Moore
WCWenning Chu
Wenning Chu
SMStefano Menegatti
Stefano Menegatti

21 February 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
WCWenning Chu
Wenning Chu
SSShriarjun Shastry
Shriarjun Shastry
EBEduardo Barbieri
Eduardo Barbieri
RPRaphael Prodromou
Raphael Prodromou
PGPaul Greback-Clarke
Paul Greback-Clarke
SMStefano Menegatti
Stefano Menegatti
Adeno-associated viruses (AAVs) are the vector of choice for delivering gene therapies that can cure inherited and acquired diseases. Clinical research on various AAV serotypes significantly increased in recent years alongside regulatory approvals of AAV-based therapies. The current AAV purification platform hinges on the capture step, for which several affinity resins are commercially available. These adsorbents rely on protein ligands – typically camelid antibodies – that provide high binding capacity and selectivity, but suffer from low biochemical stability and high cost, and impose harsh elution conditions (pH < 3) that can harm the transduction activity of recovered AAVs. Addressing these challenges, this study introduces peptide ligands that selectively capture AAVs and release them under mild conditions (pH 6.0). The peptide sequences were identified by screening a focused library and modeled in silico against AAV serotypes 2 and 9 (AAV2 and AAV9) to select candidate ligands that target homologous sites at the interface of the VP1-VP2 and VP2-VP3 virion proteins with mild binding strength (K D ∼ 10 - 5 -10 -6 M). Selected peptides were conjugated to Toyopearl resin and evaluated via binding studies against AAV2 and AAV9, demonstrating the ability to target both serotypes with values of dynamic binding capacity (DBC 10% > 10 13 vp per mL of resin) and product yields (∼50-80%) on par with commercial adsorbents. The peptide-based adsorbents were finally utilized to purify AAV2 from a HEK 293 cell lysate, affording high recovery (50-80%), 80-to-400-fold reduction of host cell proteins (HCPs), and high transduction activity (up to 80%) of the purified viruses.